COV:CA:CDX-Covalon Technologies Ltd (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 3.4

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Covalon Technologies Ltd is engaged in the business of developing, licensing, and selling medical technologies. The Company generates its revenues through development contracts, licensing agreements, and distribution contracts and sales.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.19B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
MIR:CA MedMira Inc

N/A

USD 0.06B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

N/A

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.67M

ETFs Containing COV:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 220.75% 82% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 220.75% 82% B 84% B
Trailing 12 Months  
Capital Gain 126.67% 75% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 126.67% 75% C 80% B-
Trailing 5 Years  
Capital Gain 49.12% 50% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.12% 50% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 9.96% N/A N/A 60% D-
Dividend Return 9.96% N/A N/A 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.08% N/A N/A 50% F
Risk Adjusted Return 18.42% N/A N/A 64% D
Market Capitalization 0.05B 89% A- 90% A-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector